Cargando…
Comparison of different medical treatment options for CRSwNP: doxycycline, methylprednisolone, mepolizumab and omalizumab
Autores principales: | De Schryver, Els, Calus, Lien, Van Zele, Thibaut, Bachert, Claus, Gevaert, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493504/ http://dx.doi.org/10.1186/2045-7022-5-S4-P41 |
Ejemplares similares
-
EUFOREA consensus on biologics for CRSwNP with or without asthma
por: Fokkens, Wytske J., et al.
Publicado: (2019) -
Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
por: Bachert, Claus, et al.
Publicado: (2022) -
Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds
por: Chuang, Chien‐Chia, et al.
Publicado: (2021) -
Clinical characteristics of patients with CRSwNP with intensely high eosinophil level
por: Ma, Ling, et al.
Publicado: (2022) -
Adverse events for biologics in patients with CRSwNP: A meta‐analysis
por: Shen, Yang, et al.
Publicado: (2022)